These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24726056)

  • 1. Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma.
    Goto H; Kojima Y; Matsuda K; Kariya R; Taura M; Kuwahara K; Nagai H; Katano H; Okada S
    Eur J Cancer; 2014 Jul; 50(10):1836-1846. PubMed ID: 24726056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A potential role of the NOD genetic background in mouse peritoneal macrophages for the development of primary effusion lymphoma.
    Goto H; Kariya R; Matsuda K; Kudo E; Katano H; Okada S
    Leuk Res; 2016 Mar; 42():37-42. PubMed ID: 26859781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
    Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
    Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
    Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
    Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting VEGF and interleukin-6 for controlling malignant effusion of primary effusion lymphoma.
    Goto H; Kudo E; Kariya R; Taura M; Katano H; Okada S
    J Cancer Res Clin Oncol; 2015 Mar; 141(3):465-74. PubMed ID: 25304617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid liposomes inhibit the growth of primary effusion lymphoma in vitro and in vivo.
    Towata T; Komizu Y; Suzu S; Matsumoto Y; Ueoka R; Okada S
    Leuk Res; 2010 Jul; 34(7):906-11. PubMed ID: 20074798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A fully human anti-CD47 blocking antibody with therapeutic potential for cancer.
    Zeng D; Sun Q; Chen A; Fan J; Yang X; Xu L; Du P; Qiu W; Zhang W; Wang S; Sun Z
    Oncotarget; 2016 Dec; 7(50):83040-83050. PubMed ID: 27863402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
    Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
    Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
    Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
    Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF-κB pathway.
    Goto H; Kariya R; Shimamoto M; Kudo E; Taura M; Katano H; Okada S
    Cancer Sci; 2012 Apr; 103(4):775-81. PubMed ID: 22320346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer.
    Shimizu A; Sawada K; Kobayashi M; Yamamoto M; Yagi T; Kinose Y; Kodama M; Hashimoto K; Kimura T
    Mol Cancer Res; 2021 Sep; 19(9):1583-1595. PubMed ID: 34016744
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cucurbitacin B induces apoptosis of primary effusion lymphoma via disruption of cytoskeletal organization.
    Ueno M; Kariya R; Sittithumcharee G; Okada S
    Phytomedicine; 2021 May; 85():153545. PubMed ID: 33799222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biscoclaurine alkaloid cepharanthine inhibits the growth of primary effusion lymphoma in vitro and in vivo and induces apoptosis via suppression of the NF-kappaB pathway.
    Takahashi-Makise N; Suzu S; Hiyoshi M; Ohsugi T; Katano H; Umezawa K; Okada S
    Int J Cancer; 2009 Sep; 125(6):1464-72. PubMed ID: 19521981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antitumor effects of methyl-β-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts.
    Gotoh K; Kariya R; Alam MM; Matsuda K; Hattori S; Maeda Y; Motoyama K; Kojima A; Arima H; Okada S
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):285-9. PubMed ID: 25446086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma.
    Panaampon J; Kariya R; Okada S
    Cancer Immunol Immunother; 2022 May; 71(5):1017-1031. PubMed ID: 34545416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential.
    Liu J; Wang L; Zhao F; Tseng S; Narayanan C; Shura L; Willingham S; Howard M; Prohaska S; Volkmer J; Chao M; Weissman IL; Majeti R
    PLoS One; 2015; 10(9):e0137345. PubMed ID: 26390038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV protease inhibitor Lopinavir induces apoptosis of primary effusion lymphoma cells via suppression of NF-κB pathway.
    Kariya R; Taura M; Suzu S; Kai H; Katano H; Okada S
    Cancer Lett; 2014 Jan; 342(1):52-9. PubMed ID: 24012878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elimination of tumor by CD47/PD-L1 dual-targeting fusion protein that engages innate and adaptive immune responses.
    Liu B; Guo H; Xu J; Qin T; Guo Q; Gu N; Zhang D; Qian W; Dai J; Hou S; Wang H; Guo Y
    MAbs; 2018; 10(2):315-324. PubMed ID: 29182441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. YM155 induces apoptosis through proteasome-dependent degradation of MCL-1 in primary effusion lymphoma.
    Kojima Y; Hayakawa F; Morishita T; Sugimoto K; Minamikawa Y; Iwase M; Yamamoto H; Hirano D; Imoto N; Shimada K; Okada S; Kiyoi H
    Pharmacol Res; 2017 Jun; 120():242-251. PubMed ID: 28396094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel fully human anti-CD47 antibodies stimulate phagocytosis and promote elimination of AML cells.
    Wang C; Sun C; Li M; Xia B; Wang Y; Zhang L; Zhang Y; Wang J; Sun F; Lu S; Zhu J; Huang J; Zhang Y
    J Cell Physiol; 2021 Jun; 236(6):4470-4481. PubMed ID: 33206395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.